PATENT ABSTRACTS

such that circulation is effected in the cell cul- turing space.

4806415

M E T H O D A N D S Y S T E M F O R D E T E R M I N I N G T H E P R E S E N C E

O F A D E N O S I N E T R I P H O S P H A T E O R F L A V I N M O N O N U C L E O T I D E

Piero Fossati, Buonarroti, Italy assigned to Miles Inc

An enzymatic determination of one of the co- enzymes adenosine triphosphate (ATP) or flavin mono-nucleotide (FMN) based on the use of an flavine adenine dinucleotide (FAD) syntbetase- active system in conjunction with the other coen- zyme to generate FAD. The generated FAD can then be measured to determine the ATP or FMN concentration in the sample. Preferably, the generated FAD is measured by combination with a corresponding apoenzyme, preferably apo (glucose oxidase), and measuring the ac- tivity of the enzyme produced. The resultant ac- tive enzyme is preferably measured in a manner which results in a colorimetric response. The pre- sent invention provides an ATP or FMN assay which combines the sensitivity of bioluminescent assays with the convenience of a colorimetrically detectable response.

4806463

I N H I B I T I O N O F H T L V - I I I BY E X O G E N O U S

O L I G O N U C L E O T I D E S

John Goodchild, Paul C Zamecnik assigned to Worcester Foundation for Experimental Bio- logy

Inhibition of HTLV-III by adminstration of an oligonucleotide complementary to highly con- served regions of the HTLV-III genome neces- sary for HTLV-III replication and/or gene expression is described, as are oligodeox- ynucleotide sequences which are complementary to those regions, methods of inhibiting HTLV- III replication and gene expression and methods of determining the presence or absence of HTLV-III virus in samples such as blood, saliva, urine and tears.

283

4806464

N U C L E A R B I N D I N G A S S A Y F O R S T E R O I D R E C E P T O R F U N C T I O N A L I T Y I N C A N C E R O U S C E L L S

Thomas Spelsberg assigned to Mayo Founda- tion for Medical Education and Research

A method for rapidly determining the presence of functional cellular steroid receptors by as- saying a tissue sample for nuclear steroid or anti- steroid binding is disclosed which comprises treating the tissue with collagenase, incubating the isolated cells with a labelled steroid or a labelled antisteroid capable of complexing said receptors and measuring the bound nuclear radioactivity and the DNA of the isolated cel- lular nuclei.

4806468

M E A S U R E M E N T O F G L Y C O S Y L A T E D H E M O G L O B I N

BY I M M U N O A S S A Y

Daniel Wagner, Ashok Sinha assigned to Becton Dickinson and Company

A method for determining glycosylated hemoglobin in a diluted blood sample includes binding of glycosylated hemoglobin to a specific monoclonal antibody and binding of non- glycosylated hemoglobin to a polyclonal anti- body. The polyclonal antibody binds to all hemoglobin fractions and blocks the peroxidase activity thereof, except glycosylated hemoglobin bound to the monoclonal antibody which retains peroxidase activity. A beam of light having a wavelength of about 416 nm is passed through the assay medium and is absorbed by all hemoglobin fractions, bound or unbound, and this absorbance thereby provides a measure of total hemoglobin. Hydrogen peroxide and a peroxidase substrate are added. The substrate is oxidized by the peroxide to a product having an absorbance at a wavelength different from 416 nm, the oxidation being catalyzed by the retained peroxidase activity of the bound glycosylated hemoglobin. This absorbance pro- vides a measure of glycosylated hemoglobin. From the two absorbances, the percentage of glycosylated hemoglobin in the total hemoglobin of the sample may be calculated. The invention includes a kit of materials useful in performing the assay method of the invention.